Browse medicines, page 2 of 6

Use listed on the medicine record

And pediatric patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular

Use listed on the medicine record

Infant botulism caused by toxin type A or B

Use listed on the medicine record

Prophylaxis to prevent attacks of hereditary angioedema

Use listed on the medicine record

Locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease

Use listed on the medicine record

Infection caused by Orthoebolavirus zairense

Use listed on the medicine record

Proteinuria

Use listed on the medicine record

Chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy

Use listed on the medicine record

The diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi

Use listed on the medicine record

Chronic hepatitis delta virus (HDV) infection

Use listed on the medicine record

X-linked hypophosphatemia

Use listed on the medicine record

Acute lymphoblastic leukemia

Use listed on the medicine record

Infection caused by susceptible strains of the designated organisms in the following diseases

Use listed on the medicine record

CARVYKTI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. CARVYKTI is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to…

Use listed on the medicine record

RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season

Use listed on the medicine record

The detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis

Use listed on the medicine record

Adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg

Use listed on the medicine record

Recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent

Use listed on the medicine record

The treatment of patients

Use listed on the medicine record

AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. ( 1 )

Use listed on the medicine record

Episodic cluster headache

Use listed on the medicine record

COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Use listed on the medicine record

Adults and pediatric patients 2 years of age and older with primary humoral immunodeficiency

Use listed on the medicine record

The prophylaxis and treatment of acute rejection

Use listed on the medicine record

OTARMENI is indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the OTOF gene, preserved outer hair cell function, and no prior cochlear implant in the same ear. This indication is approved under accelerated approval based on the improvement of hearing sensitivity assessed by average pure tone audiometry (PTA) at Week 24 [see Clinical Studies (14) ] .

Use listed on the medicine record

Metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was

Use listed on the medicine record

Adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy

Use listed on the medicine record

Prurigo nodularis

Use listed on the medicine record

Skeletal imaging to demonstrate areas of altered osteogenesis

Use listed on the medicine record

Exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy

Use listed on the medicine record

Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.